Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Gattermann

Showing results (91-100 of 109) with videos related to

Pageof 11
Sort By:
Deutsche Medizinische Wochenschrift (1946)|October 20, 2011
[Multimodal therapy in locally advanced gastric cancer]E Bölke, M Peiper, W T Knoefel, et al.
Leukemia|June 26, 2013
Insufficient stromal support in MDS results from molecular and functional deficits of mesenchymal stromal cellsS Geyh, S Oz, R-P Cadeddu, et al.
Ecancermedicalscience|January 26, 2012
Azacitidine prolongs overall survival and reduces infections and hospitalizations in patients with WHO-defined acute myeloid leukaemia compared with conventional care regimens: an updateP Fenaux, G J Mufti, E Hellström-Lindberg, et al.
European Journal of Medical Research|October 26, 2011
Trimodal therapy in squamous cell carcinoma of the esophagusC Matuschek, E Bölke, T Zahra, et al.
Leukemia Research|August 4, 2018
The IPSS-R has prognostic impact in untreated patients with MDS del(5q)J Kaivers, M Lauseker, B Hildebrandt, et al.
Leukemia|January 26, 2007
Molecular signature of CD34(+) hematopoietic stem and progenitor cells of patients with CML in chronic phaseE Diaz-Blanco, I Bruns, F Neumann, et al.
Leukemia|September 30, 2005
Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS)U Germing, B Hildebrandt, M Pfeilstöcker, et al.
Leukemia|January 23, 2009
The hematopoietic stem cell in chronic phase CML is characterized by a transcriptional profile resembling normal myeloid progenitor cells and reflecting loss of quiescenceI Bruns, A Czibere, J C Fischer, et al.
Annals of Hematology|June 24, 2016
Health care setting and severity, symptom burden, and complications in patients with Philadelphia-negative myeloproliferative neoplasms (MPN): a comparison between university hospitals, community hospitals, and office-based physiciansA Kaifie, S Isfort, N Gattermann, et al.
Leukemia|December 16, 2015
Results of a multicenter prospective phase II trial investigating the safety and efficacy of lenalidomide in patients with myelodysplastic syndromes with isolated del(5q) (LE-MON 5)E Schuler, A Giagounidis, D Haase, et al.
Pageof 11

Showing results (91-100 of 109) with videos related to

Sort By:
Pageof 11
Deutsche Medizinische Wochenschrift (1946)|October 20, 2011
[Multimodal therapy in locally advanced gastric cancer]E Bölke, M Peiper, W T Knoefel, et al.
Leukemia|June 26, 2013
Insufficient stromal support in MDS results from molecular and functional deficits of mesenchymal stromal cellsS Geyh, S Oz, R-P Cadeddu, et al.
Ecancermedicalscience|January 26, 2012
Azacitidine prolongs overall survival and reduces infections and hospitalizations in patients with WHO-defined acute myeloid leukaemia compared with conventional care regimens: an updateP Fenaux, G J Mufti, E Hellström-Lindberg, et al.
European Journal of Medical Research|October 26, 2011
Trimodal therapy in squamous cell carcinoma of the esophagusC Matuschek, E Bölke, T Zahra, et al.
Leukemia Research|August 4, 2018
The IPSS-R has prognostic impact in untreated patients with MDS del(5q)J Kaivers, M Lauseker, B Hildebrandt, et al.
Leukemia|January 26, 2007
Molecular signature of CD34(+) hematopoietic stem and progenitor cells of patients with CML in chronic phaseE Diaz-Blanco, I Bruns, F Neumann, et al.
Leukemia|September 30, 2005
Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS)U Germing, B Hildebrandt, M Pfeilstöcker, et al.
Leukemia|January 23, 2009
The hematopoietic stem cell in chronic phase CML is characterized by a transcriptional profile resembling normal myeloid progenitor cells and reflecting loss of quiescenceI Bruns, A Czibere, J C Fischer, et al.
Annals of Hematology|June 24, 2016
Health care setting and severity, symptom burden, and complications in patients with Philadelphia-negative myeloproliferative neoplasms (MPN): a comparison between university hospitals, community hospitals, and office-based physiciansA Kaifie, S Isfort, N Gattermann, et al.
Leukemia|December 16, 2015
Results of a multicenter prospective phase II trial investigating the safety and efficacy of lenalidomide in patients with myelodysplastic syndromes with isolated del(5q) (LE-MON 5)E Schuler, A Giagounidis, D Haase, et al.
Pageof 11